FindTrial
Sign In

Muscle Loss and Obesity in Diabetic Adults in India: How Common is it, and How Can We Predict It

Sarcopenia and Sarcopenic Obesity in Adults with Type 2 Diabetes Mellitus in Resource-Limited Settings in India: Epidemiology, Biomarker Profiles, Bone Health,and Development of a Novel Risk Prediction Tool - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106807
Enrollment
300
Registered
2026-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Nil: Nil

Sponsors

Endocrine Society of India Ad Hoc Grant
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Type 1 diabetes, pancreatic diabetes, or other forms of diabetes.Pregnancy.Established CKD, CVA, CAD, CLD.Immobility or restricted mobility due to any reason.Use of medications such as steroids (including anabolic steroids), estrogen, or testosterone.

Exclusion criteria

Exclusion criteria: Type 1 diabetes, pancreatic diabetes, or other forms of diabetes.Pregnancy.Established CKD, CVA, CAD, CLD.Immobility or restricted mobility due to any reason.Use of medications such as steroids (including anabolic steroids), estrogen, or testosterone.

Design outcomes

Primary

MeasureTime frame
To determine the proportion, nutritional and physical activity related determinants of sarcopenia in adults aged 20-60 years with type 2 diabetes.Timepoint: Being a cross-sectional study, the primary outcome will be determined at the time of recruitment without any further follow-up. Recruitment period is 18months.—

Secondary

MeasureTime frame
1.To assess the relationship between sarcopenia, sarcopenic obesity & bone health 2. To assess the quality of life in adults aged 20-60 years living with sarcopenia & type 2 diabetes. 3. To develop a predictive tool for sarcopenia in adults with type 2 diabetes 4. To determine the biomarkers associated with sarcopenia & sarcopenic obesity in adults with type 2 diabetes.Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Akhila Bhandarkar

KS Hegde Medical Academy

drakhila.bhandarkar@gmail.com09971508069

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026